Dr. Sotirios Stergiopoulos is Chief Medical officer and Senior Vice President, Head of Global Medical Affairs and a member of the R&D Leadership team at Ipsen BioSciences. Sotirios has extensive experience in directing medical affairs worldwide strategies and plans and a solid expertise in Oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumor indications. Dr. Stergiopoulos is also the Chair of the Board of Directors of a young start-up company, A2A Pharmaceuticals, a fragment based computational drug design company.
Dr. Stergiopoulos earned his M.D at the University of Medical Sciences of Poznan, Poland. He completed his residency in Internal Medicine at the Albert Einstein College of Medicine (NY), Sotirios also had completed a clinical and research fellowship in Medical Genetics at Harvard Medical School and a research fellowship at National Institutes of Health. Sotirios holds a Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from The Johns Hopkins University (Baltimore, MD).
Dr. Stergiopoulos has held the appointment of Attending Physician in the Department of Internal Medicine at Jacobi Medical Center, Albert Einstein College of Medicine (NY). He has been elected as President of the Board of Governors of the Accreditation Council of Medical Affairs (ACMA), a credentialed body that serves to educate and train scientists and medics in Medical Affairs. Sotirios is a Fellow of the American College of Physicians, the New York Academy of Medicine as well as the Royal Society of Medicine (UK). He also is a Member of the American Association of Cancer Research and American Society of Clinical Oncology.